Automated solid-phase peptide synthesis to obtain therapeutic peptides

Area of Science:

• Medicinal Chemistry
• Biotechnology
• Pharmaceutical Sciences

Background:

• Peptides exhibit high target affinity but suffer from instability and rapid clearance, limiting their therapeutic use.
• Chemical modifications are crucial for improving peptide drugability and pharmacokinetic profiles.
• Automated solid-phase peptide synthesis (SPPS) provides a robust platform for producing chemically engineered peptides.

Purpose of the Study:

• To review the application of Fmoc/t-Bu based automated solid-phase peptide synthesis (SPPS) for therapeutic peptide development.
• To discuss critical aspects, advancements, and strategies in automated peptide synthesis.
• To highlight methods for improving peptide pharmacokinetic properties through chemical modifications.

Main Methods:

• Focus on Fmoc/t-Bu protecting-group strategy in automated solid-phase peptide synthesis (SPPS).
• Discussion of conventional and microwave-assisted automated synthesis instruments.
• Description of covalent conjugation techniques like lipidation and PEGylation for pharmacokinetic enhancement.

Main Results:

• SPPS, particularly with Fmoc/t-Bu strategy, is a key technology for synthesizing modified peptides.
• Microwave-assisted SPPS offers significant improvements over conventional methods.
• Lipidation and PEGylation are effective strategies for improving peptide stability and duration of action.

Conclusions:

• Optimized automated SPPS technologies are vital for manufacturing novel peptide drug candidates.
• Chemical engineering of peptides via SPPS and conjugation methods leads to improved therapeutic potential.
• The synthesis of neuropeptide Y receptor analogs exemplifies the power of these advanced peptide synthesis strategies.